Participation of Protein Kinases in the Stimulant Action of GLP-1 on 2-deoxy-D-glucose Uptake by Normal Rat Skeletal Muscle

Abstract

Several protein kinases were recently proposed for involvement in GLP-1-stimulated D-glucose transport in skeletal muscle from both normal subjects and type 2 diabetic patients. This study was mainly aimed at investigating the effect of potential inhibitors of distinct protein kinases and protein phosphatase-1 upon insulin- and GLP-1-stimulated 2-deoxy-D-glucose net uptake by normal rat skeletal muscle. The basal uptake of the D-glucose analog was decreased by wortmannin - a phosphatidylinositol-3-kinase inhibitor -, PD98059 - a mitogen-activated protein kinases inhibitor -, and TNFα - a protein phosphatase-1 inhibitor -, but not by either rapamycin - a p70s6 kinase inhibitor -, or H-7 -, a protein kinase C inhibitor -. The enhancing action of both insulin and GLP-1 upon 2-deoxy-D-glucose transport was abolished by PD98059 and H-7, but largely unaffected by TNFα. Wortmannin and rapamycin preferentially affected the response to GLP-1 and insulin, respectively. These findings thus document both analogies and dissimilarities in the participation of the concerned enzymes in the stimulant action of insulin versus GLP-1 upon D-glucose transport in normal rat skeletal muscle.

Glucose transport - Protein kinases

References

• 1 Creutzfeldt W. The entero-insular axis in type 2 diabetes. Incretins as therapeutic agents.  Exp Clin Endocrinol Diabetes. 2001;  109, suppl 2 S288-S303
• 2 Gutniak M, Orskov C, Holst J J, Ahrén B, Efendic S. Antidiabetogenic effects of glucagon-like peptide-1(7 - 36)amide in normal subjects and patients with diabetes mellitus.  N Engl J Med. 1992;  326 1316-1322
• 3 D'Alessio D A, Prigeon R L, Ensinck J W. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I.  Diabetes. 1995;  44 1433-1437
• 4 Ehlers M R, Klaff L J, D'Alessio D A, Brazg R, Kay H D, Harley R E, Mathisen A L, Schneider R. Recombinant glucagon-like peptide-1 (7 - 36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.  Horm Metab Res. 2003;  35 611-616
• 5 Valverde I, Morales M, Clemente F, López-Delgado M I, Delgado E, Perea A, Villanueva-Peñacarrillo M L. Glucagon-like peptide-1: a potent glycogenic hormone.  FEBS Lett. 1994;  349 313-316
• 6 Villanueva-Peñacarrillo M L, Alcántara A, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1 (7 - 36) amide in rat skeletal muscle.  Diabetologia. 1994;  37 1163-1166
• 7 Perea A, Viñambres C, Clemente F, Villanueva-Peñacarrillo M L, Valverde I. GLP-1(7 - 36)amide effects on glucose transport and metabolism in rat adipose tissue.  Horm Metab Res. 1997;  9 417-421
• 8 Villanueva-Peñacarrillo M L, Márquez L, González N, Díaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes.  Horm Metab Res. 2001;  33 73-77
• 9 Morales M, López-Delgado M I, Alcántara A, Luque M A, Clemente F, Márquez L, Puente J, Viñambres C, Malaisse W J, Villanueva-Peñacarrillo M L, Valverde I. Preserved GLP-1 effects upon glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats.  Diabetes. 1997;  46 1264-1269
• 10 Mérida E, Delgado E, Molina L M, Villanueva-Peñacarrillo M L, Valverde I. Presence of glucagon and glucagon-like peptide-1(7 - 36)amide receptors in solubilized membranes of human adipose tissue.  J Clin Endocrinol Metab. 1993;  77 1654-1657
• 11 Valverde I, Mérida E, Delgado E, Trapote M A, Villanueva-Peñacarrillo M L. Presence and characterization of glucagon-like peptide-1(7 - 36) amide receptors in solubilized membranes of rat adipose tissue.  Endocrinology. 1993;  132 75-79
• 12 Delgado E, Luque M A, Alcántara A, Trapote M A, Clemente F, Galera C, Valverde I, Villanueva-Peñacarrillo M L. Glucagon-like peptide-1 binding to rat skeletal muscle.  Peptides. 1995;  16 225-229
• 13 Villanueva-Peñacarrillo M L, Delgado E, Trapote M A, Alcántara A I, Clemente F, Luque M A, Perea A, Valverde I. Glucagon-like peptide-1 binding to rat hepatic membranes.  J Endocrinol. 1995;  146 183-189
• 14 Yang H, Egan J M, Wang Y, Moyes D, Roth J, Montrose M H, Montrose-Rafizadeh C. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.  Am J Physiol. 1998;  275 C675-C683
• 15 Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide-1.  Proc Natl Acad Sci USA. 1992;  89 8641-8645
• 16 Luque M A, González N, Márquez L, Acitores A, Redondo A, Morales M, Valverde I, Villanueva-Peñacarrillo M L. GLP-1 and glucose metabolism in human myocytes.  J Endocrinol. 2002;  173 465-473
• 17 González N, Acitores A, Sancho V, Valverde I, Villanueva-Peñacarrillo M L. Effect of GLP-1 on glucose transport and its cell signaling in human myocytes.  Regul Pept. 2005;  126 203-211
• 18 Wang Y, Kole H K, Montrose-Rafizadeh C, Perfetti R, Bernier M, Egan J M. Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions.  J Mol Endocrinol. 1997;  19 241-248
• 19 Villanueva-Peñacarrillo M L, Puente J, Redondo A, Clemente F, Valverde I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in NIDDM and IDDM rats.  Endocrine. 2001;  15 241-248
• 20 Acitores A, González N, Sancho V, Valverde I, Villanueva-Peñacarrillo M L. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle.  J Endocrinol. 2004;  180 389-398
• 21 Redondo A, Trigo M V, Acitores A, Valverde I, Villanueva-Peñacarrillo M L. Cell signalling of the GLP-1 action in rat liver.  Mol Cell Endocrinol. 2003;  204 43-50
• 22 Sancho V, Trigo M V, González N, Valverde I, Malaisse W J, Villanueva-Peñacarrillo M L. Effects of GLP-1 and exending on kinase activity, 2-deoxy-D-glucose transport, lipolysis and lipogenesis in adipocytes from normal and streptozotocin-induced type 2 diabetic rats.  J Mol Endocrinol. 2005;  in press
• 23 González N, Sancho V, Martín-Duce A, Torneo-Esteban P, Valverde I, Malaisse W J, Villanueva-Peñacarrillo M L. GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients. Submitted for publication. 
• 24 Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding.  Anal Biochem. 1976;  72 248-254
• 25 Dohm G L, Tapscott E B, Pories W J, Dabbs D J, Flickinger E G, Meelheim T F, Atkinson S M, Elton C W, Caro J F. An in vitro human muscle preparation suitable for metabolic studies.  J Clin Invest. 1988;  82 486-494
• 26 Dent P, Lavoinne A, Nakielny S, Caudwell F B, Watt P, Cohen P. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle.  Nature. 1990;  348 302-308
• 27 Lazar D F, Wiese R J, Brady M J, Mastick C C, Waters S B, Yamauchi K, Pessin J E, Cuatrecasas P, Saltiel A R. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin.  J Biol Chem. 1995;  270 20 801-20 807
• 28 Cross D AE, Alessi D R, Cohen P, Andjelkovich M, Hemmings B A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase 3.  Nature (London). 1995;  378 785-789
• 29 Hurel S J, Rochford J J, Borthwick A C, Wells A M, Vandenheede J R, Tumbull D M, Yeaman S J. Insulin action in cultured human myoblasts: contribution of different signalling pathways to regulation of glycogen synthesis.  Biochem J. 1996;  320 871-877
• 30 Peak M, Rochford J J, Borthwick A C, Yeaman S J, Agius L. Signalling pathways involved in the stimulation of glycogen synthesis by insulin in rat hepatocytes.  Diabetologia. 1998;  41 16-25
• 31 Ragolia L, Begum N. Protein phosphatase-1 and insulin action.  Cell Biochem. 1998;  182 49-58